Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2006

Open Access 01-12-2006 | Hypothesis

Can the state of cancer chemotherapy resistance be reverted by epigenetic therapy?

Authors: Carlos Perez-Plasencia, Alfonso Duenas-Gonzalez

Published in: Molecular Cancer | Issue 1/2006

Login to get access

Abstract

Background

Transcriptome analysis shows that the chemotherapy innate resistance state of tumors is characterized by: poorly dividing tumor cells; an increased DNA repair; an increased drug efflux potential by ABC-transporters; and a dysfunctional ECM. Because chemotherapy resistance involves multiple genes, epigenetic-mediated changes could be the main force responsible of this phenotype. Our hypothesis deals with the potential role of epigenetic therapy for affecting the chemotherapy resistant phenotype of malignant tumors.

Presentation of the hypothesis

Recent studies reveal the involvement of DNA methylation and histone modifications in the reprogramming of the genome of mammalian cells in cancer. In this sense, it can be hypothesized that epigenetic reprogramming can participate in the establishment of an epigenetic mark associated with the chemotherapy resistant phenotype. If this were correct, then it could be expected that agents targeting DNA methylation and histone deacetylation would by reverting the epigenetic mark induce a global expression profile that mirror the observed in untreated resistant cells.

Testing the hypothesis

It is proposed to perform a detailed analysis using all the available databases where the gene expression of primary tumors was analyzed and data correlated with the therapeutic outcome to determine whether a transcriptome profiling of "resistance" is observed. Assuming an epigenetic programming determines at some level the intrinsic resistant phenotype, then a similar pattern of gene expression dictated by an epigenetic mark should also be found in cell acquiring drug resistance. If these expectations are meet, then it should be further investigated at the genomic level whether these phenotypes are associated to certain patterns of DNA methylation and chromatin modification. Once confirmed the existence of an epigenetic mark associated to either the intrinsic or acquired chemotherapy resistant phenotype, then a causal association should be investigated. These preclinical findings should also be tested in a clinical setting.

Implications of the hypothesis

Our hypothesis on the ability of epigenetic therapy to revert the epigenetic changes leading to a transcritome profile that defines the resistant state will eventually be a more rational and effective way to treat malignant tumors.
Appendix
Available only for authorised users
Literature
1.
Lage H: ABC-transporters: implications on drug resistance from microorganisms to human cancers. Int J Antimicrob Agents. 2003, 22: 188-199. 10.1016/S0924-8579(03)00203-6CrossRefPubMed
2.
Townsend DM, Tew KD: The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene. 2003, 22: 7369-7375. 10.1038/sj.onc.1206940CrossRefPubMed
3.
Mashima T, Tsuruo T: Defects of the apoptotic pathway as therapeutic target against cancer. Drug Resist Updat. 2005, 8: 339-343. 10.1016/j.drup.2005.11.001CrossRefPubMed
4.
Oza AM: Clinical development of P glycoprotein modulators in oncology. Novartis Found Symp. 2002, 243: 103-115.CrossRefPubMed
5.
Choi CH: ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. Cancer Cell Int. 2005, 5: 30- 10.1186/1475-2867-5-30PubMedCentralCrossRefPubMed
6.
Weinstein IB: Disorders in cell circuitry during multistage carcinogenesis: the role of homeostasis. Carcinogenesis. 2000, 21: 857-864. 10.1093/carcin/21.5.857CrossRefPubMed
7.
Baylin SB, Ohm JE: Epigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction?. Nat Rev Cancer. 2006, 6: 107-116. 10.1038/nrc1799CrossRefPubMed
8.
Yap Y, Zhang X, Ling MT, Wang X, Wong YC, Danchin A: Classification between normal and tumor tissues based on the pair-wise gene expression ratio. BMC Cancer. 2004, 4: 72- 10.1186/1471-2407-4-72PubMedCentralCrossRefPubMed
9.
Warnat P, Eils R, Brors B: Cross-platform analysis of cancer microarray data improves gene expression based classification of phenotypes. BMC Bioinformatics. 2005, 6: 265- 10.1186/1471-2105-6-265PubMedCentralCrossRefPubMed
10.
Gabriele L, Moretti F, Pierotti MA, Marincola FM, Foà R, Belardelli FM: The use of microarray technologies in clinical oncology. J Transl Med. 2006, 4: 8- 10.1186/1479-5876-4-8PubMedCentralCrossRefPubMed
11.
Graudens E, Boulanger V, Mollard C, Mariage-Samson R, Barlet X, Gremy G, Couillault C, Lajemi M, Piatier-Tonneau D, Zaborski P, Eveno E, Auffray C, Imbeaud S: Deciphering cellular states of innate tumor drug responses. Genome Biol. 2006, 7: R19- 10.1186/gb-2006-7-3-r19PubMedCentralCrossRefPubMed
12.
Di Nicolantonio F, Mercer SJ, Knight LA, Gabriel FG, Whitehouse PA, Sharma S, Fernando A, Glaysher S, Di Palma S, Johnson P, Somers SS, Toh S, Higgins B, Lamont A, Gulliford T, Hurren J, Yiangou C, Cree IA: Cancer cell adaptation to chemotherapy. BMC Cancer. 2005, 5: 78- 10.1186/1471-2407-5-78PubMedCentralCrossRefPubMed
13.
Glasspool RM, Teodoridis JM, Brown R: Epigenetics as a mechanism driving polygenic clinical drug resistance. Br J Cancer. 2006, 94: 1087-1092. 10.1038/sj.bjc.6603024PubMedCentralCrossRefPubMed
14.
Baker EK, El-Osta A: The rise of DNA methylation and the importance of chromatin on multidrug resistance in cancer. Exp Cell Res. 2003, 290: 177-194. 10.1016/S0014-4827(03)00342-2CrossRefPubMed
15.
Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB: Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet. 1999, 21: 103-107. 10.1038/5047CrossRefPubMed
16.
Shi H, Wei SH, Leu YW, Rahmatpanah F, Liu JC, Yan PS, Nephew KP, Huang TH: Triple analysis of the cancer epigenome: an integrated microarray system for assessing gene expression, DNA methylation, and histone acetylation. Cancer Res. 2003, 63: 2164-2171.PubMed
17.
Li L, Shi H, Yiannoutsos C, Huang TH, Nephew KP: Epigenetic hypothesis tests for methylation and acetylation in a triple microarray system. J Comput Biol. 2005, 12: 370-390. 10.1089/cmb.2005.12.370CrossRefPubMed
18.
Chavez-Blanco A, Perez-Plasencia C, Perez-Cardenas E, Carrasco-Legleu C, Rangel-Lopez E, Segura-Pacheco B, Taja-Chayeb L, Trejo-Becerril C, Gonzalez-Fierro A, Candelaria M, Cabrera G, Duenas-Gonzalez A: Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines. Cancer Cell Int. 2006, 6: 2- 10.1186/1475-2867-6-2PubMedCentralCrossRefPubMed
19.
Hsiao HL, Wang WS, Chen PM, Su Y: Overexpression of thymosin {beta}-4 renders SW480 colon carcinoma cells more resistant to apoptosis triggered by FasL and two topoisomerase II inhibitors via downregulating Fas and upregulating Survivin expression, respectively. Carcinogenesis. 2006, 27: 936-944. 10.1093/carcin/bgi316CrossRefPubMed
20.
Sergent C, Franco N, Chapusot C, Lizard-Nacol S, Isambert N, Correia M, Chauffert B: Human colon cancer cells surviving high doses of cisplatin or oxaliplatin in vitro are not defective in DNA mismatch repair proteins. Cancer Chemother Pharmacol. 2002, 49: 445-452. 10.1007/s00280-002-0450-6CrossRefPubMed
21.
Liu L, Taverna P, Whitacre CM, Chatterjee S, Gerson SL: Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents. Clin Cancer Res. 1999, 5: 2908-2917.PubMed
22.
Feinberg AP, Cui H, Ohlsson R: DNA methylation and genomic imprinting: insights from cancer into epigenetic mechanisms. Semin Cancer Biol. 2002, 12: 389-398. 10.1016/S1044-579X(02)00059-7CrossRefPubMed
23.
24.
Fruhwald MC, Plass C: Global and gene-specific methylation patterns in cancer: aspects of tumor biology and clinical potential. Mol Genet Metab. 2002, 75: 1-16. 10.1006/mgme.2001.3265CrossRefPubMed
25.
Neumeister P, Albanese C, Balent B, Greally J, Pestell RG: Senescence and epigenetic dysregulation in cancer. Int J Biochem Cell Biol. 2002, 34: 1475-1490. 10.1016/S1357-2725(02)00079-1CrossRefPubMed
26.
Tycko B: Genetic and epigenetic mosaicism in cancer precursor tissues. Ann N Y Acad Sci. 2003, 983: 43-54.CrossRefPubMed
27.
Al-Shahrour F, Minguez P, Vaquerizas JM, Conde L, Dopazo J: BABELOMICS: a suite of web tools for functional annotation and analysis of groups of genes in high-throughput experiments. Nucleic Acids Res. 2005, 33: W460-464. 10.1093/nar/gki456PubMedCentralCrossRefPubMed
28.
29.
Teodoridis JM, Strathdee G, Brown R: Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker. Drug Resist Updat. 2004, 7: 267-278. 10.1016/j.drup.2004.06.005CrossRefPubMed
30.
Baker EK, Johnstone RW, Zalcberg JR, El-Osta A: Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs. Oncogene. 2005, 24: 8061-8075. 10.1038/sj.onc.1208955CrossRefPubMed
31.
Tian K, Jurukovski V, Wang XP, Kaplan MH, Xu H: Epigenetic regulation of WTH3 in primary and cultured drug-resistant breast cancer cells. Cancer Res. 2005, 65: 10024-10031. 10.1158/0008-5472.CAN-05-1944CrossRefPubMed
32.
Nyce JW: Drug-induced DNA hypermethylation: a potential mediator of acquired drug resistance during cancer chemotherapy. Mutat Res. 1997, 386: 153-161. 10.1016/S1383-5742(96)00051-8CrossRefPubMed
33.
Nyce J, Leonard S, Canupp D, Schulz S, Wong S: Epigenetic mechanisms of drug resistance: drug-induced DNA hypermethylation and drug resistance. Proc Natl Acad Sci USA. 1993, 90: 2960-2964. 10.1073/pnas.90.7.2960PubMedCentralCrossRefPubMed
34.
Nyce J: Drug-induced DNA hypermethylation and drug resistance in human tumors. Cancer Res. 1989, 49: 5829-5836.PubMed
35.
Plumb JA, Strathdee G, Sludden J, Kaye SB, Brown R: Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res. 2000, 60: 6039-6044.PubMed
36.
Qiu YY, Mirkin BL, Dwivedi RS: Inhibition of DNA methyltransferase reverses cisplatin induced drug resistance in murine neuroblastoma cells. Cancer Detect Prev. 2005, 29: 456-463. 10.1016/j.cdp.2005.05.004CrossRefPubMed
37.
Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Y, Carrier F: Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res. 2003, 63: 7291-7300.PubMed
38.
Sonnemann J, Kumar KS, Heesch S, Muller C, Hartwig C, Maass M, Bader P, Beck JF: Histone deacetylase inhibitors induce cell death and enhance the susceptibility to ionizing radiation, etoposide, and TRAIL in medulloblastoma cells. Int J Oncol. 2006, 28: 755-766.PubMed
39.
Yoo CB, Jones PA: Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov. 2006, 5: 37-50. 10.1038/nrd1930CrossRefPubMed
40.
Cernilogar FM, Orlando V: Epigenome programming by Polycomb and Trithorax proteins. Biochem Cell Biol. 2005, 83: 322-331. 10.1139/o05-040CrossRefPubMed
Metadata
Title
Can the state of cancer chemotherapy resistance be reverted by epigenetic therapy?
Authors
Carlos Perez-Plasencia
Alfonso Duenas-Gonzalez
Publication date
01-12-2006
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2006
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-5-27

Other articles of this Issue 1/2006

Molecular Cancer 1/2006 Go to the issue

Research

In vitro and in vivo effects of the PPAR-alpha agonists fenofibrate and retinoic acid in endometrial cancer

Research

Regulation of angiogenesis and invasion by human Pituitary tumor transforming gene (PTTG) through increased expression and secretion of matrix metalloproteinase-2 (MMP-2)

Research

Sensitive detection of human papillomavirus type 16 E7-specific T cells by ELISPOT after multiple in vitro stimulations of CD8+ T cells with peptide-pulsed autologous dendritic cells

Research

Mitochondrial DNA mutations in preneoplastic lesions of the gastrointestinal tract: A biomarker for the early detection of cancer

Research

Investigation of the molecular profile of basal cell carcinoma using whole genome microarrays

Editorial

Open access and beyond
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits